Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial

R Stupp, S Taillibert, AA Kanner, S Kesari… - Jama, 2015 - jamanetwork.com
Importance Glioblastoma is the most devastating primary malignancy of the central nervous
system in adults. Most patients die within 1 to 2 years of diagnosis. Tumor-treating fields
(TTFields) are a locoregionally delivered antimitotic treatment that interferes with cell
division and organelle assembly. Objective To evaluate the efficacy and safety of TTFields
used in combination with temozolomide maintenance treatment after chemoradiation
therapy for patients with glioblastoma. Design, Setting, and Participants After completion of …